Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Oropharynx Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| SX682 (this asset) | National Cancer Institute (NCI) | P1/2 | CCC · 48 |
| Cetuximab | National Cancer Institute (NCI) | P1/2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P2 | CCC |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| had5-hpv vaccine | ImmunityBio, Inc. | P2 | CCC |
+23 more in the Oropharynx Squamous Cell Carcinoma cohort
Other indications for SX682
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Prostate Carcinoma | — | P2 | B · 60 |
| Lung Cancer | — | P2 | CCC · 53 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CetuximabNational Cancer Institute (NCI)B
- IrinotecanAIDS Malignancy ConsortiumB
- e7 tcr-t cellsChristian HinrichsB
- Cis-Diamminedichloroplatinum IiImmunityBio, Inc.CCC
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsCCC
Citation
Floatz Terminal. SX682 in Oropharynx Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sx682-oropharynx-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →